Peptide Research

THE BIG PEPTIDE SHIFT: WHAT'S CHANGING, WHAT TO EXPECT, AND WHAT IT MEANS FOR YOU 14 Peptides May Return to Legal Compounding. Here's Everything You Need to Know — In Plain English. FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY This document provides educational information about emerging regulatory developments in the pept...

YOU STOPPED YOUR GLP-1. NOW WHAT? Two-thirds of people regain the weight. Here's why — and what science says about it. Two out of three people who stop taking GLP-1 medications regain almost all their weight within 18 months. That is not a failure of willpower. It is your body doing exactly what it was designed to do. ...

WHY DID PEPTIDE SCIENCES SHUT DOWN OVERNIGHT? The inside story: FDA, Big Pharma lawsuits, and the quality failures that brought down a $7.4M/month empire. At 2:00 PM Eastern on March 6, 2026, a business generating $7.4 million per month posted three sentences on its homepage and went dark. No warning. No refund plan. No e...

PATH TO PEPTIDES GLP-1 AND SLEEP APNEA: BREATHE EASIER, SLEEP BETTER Tirzepatide became the first-ever medication approved for obstructive sleep apnea. THE FIRST DRUG FOR SLEEP APNEA — EVER About 30 million Americans have obstructive sleep apnea — a condition where your airway collapses during sleep, stopping your breat...

PATH TO PEPTIDES GLP-1 AND YOUR LIVER: THE MASH BREAKTHROUGH Fatty liver disease affects 1 in 3 adults. Semaglutide just became the first GLP-1 approved to treat it. THE SILENT EPIDEMIC IN YOUR LIVER There's a disease affecting roughly 100 million Americans that most people have never heard of. It's called MASH — metabo...

PATH TO PEPTIDES GLP-1 AND YOUR KIDNEYS: THE FLOW TRIAL BREAKTHROUGH Semaglutide now FDA-approved to protect kidneys. Here's what the science says. A FOURTH PILLAR OF KIDNEY PROTECTION Kidney disease affects 37 million Americans. Diabetes is the #1 cause. For decades, doctors had limited tools to slow kidney decline. Th...

PATH TO PEPTIDES THE GLP-1 PILL IS HERE: NO MORE NEEDLES? Oral Wegovy just got FDA-approved. Orforglipron is next. Welcome to the pill era. THE END OF THE NEEDLE ERA? For years, the biggest complaint about GLP-1 medications was simple: nobody likes shots. Weekly injections kept millions of people from even trying these ...

PATH TO PEPTIDES ANTIMICROBIAL PEPTIDES: YOUR BODY'S NATURAL DEFENSE By 2050, antibiotic-resistant infections could kill 10 million people per year. THE HOOK Antibiotics are failing. Bacteria are evolving faster than we can make new drugs. The World Health Organization calls antibiotic resistance one of the greatest thr...

PATH TO PEPTIDES COLLAGEN PEPTIDES: WHAT SCIENCE SAYS ABOUT JOINTS, TENDONS, AND SKIN Collagen supplements are a $7 billion industry. New research shows specific peptide fragments survive digestion and reach your joints. Here's what matters. FOR YEARS, CRITICS SAID COLLAGEN SUPPLEMENTS WERE USELESS — THAT YOUR STOMACH AC...

PATH TO PEPTIDES OZEMPIC FACE" AND MUSCLE LOSS: THE BODY COMPOSITION PROBLEM Up to 25% of weight lost on GLP-1 drugs is muscle, not fat. Why that matters — and what research says about protecting lean mass. HERE'S A NUMBER THAT SHOULD GET YOUR ATTENTION: STUDIES SHOW THAT UP TO 25% OF THE WEIGHT PEOPLE LOSE ON GLP-1 DRUG...